REFERENCES
1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics
Review, 1975-2016. ; 2019.
2. Stephen P. Hunger, M.D., and Charles G. Mullighan MD. Acute
Lymphoblastic Leukemia in Children. N Engl J Med .
2015;373:1541-1552.
3. Kiem Hao T, Nhu Hiep P, Kim Hoa NT, Van Ha C. Causes of Death in
Childhood Acute Lymphoblastic Leukemia at Hue Central Hospital for 10
Years (2008-2018). Glob Pediatr Heal . Published online 2020.
4. Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute
lymphoblastic leukaemia in resource-poor countries. Lancet .
Published online 2003.
5. Hoang PTV, Ambroise J, Chi VLD, et al. Comparison of long-term
outcome between white and Vietnamese children treated for acute
lymphoblastic leukemia according to the FRALLE 2000 protocol. J
Pediatr Hematol Oncol . Published online 2014.
6. Yeoh A, Tan D, Li C-K, Hori H, Tse E, Pui C-H. Oncology Summit 2013.Lancet Oncol . Published online 2014.
7. Karachunskiy A, Herold R, von Stackelberg A, et al. Results of the
first randomized multicentre trial on childhood acute lymphoblastic
leukaemia in Russia. Leukemia . 2008;22(6).
8. Yeoh AEJ, Ariffin H, Chai ELL, et al. Minimal residual disease-guided
treatment deintensification for children with acute lymphoblastic
leukemia: Results from the Malaysia-Singapore acute lymphoblastic
leukemia 2003 study. J Clin Oncol . Published online 2012.
9. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of
acute lymphoblastic leukemia can decrease treatment burden and improve
survival: Treatment results of 2169 unselected pediatric and adolescent
patients enrolled in the trial ALL-BFM 95. Blood . Published
online 2008.
10. Park KD, Hong CR, Choi JY, et al. Foundation of pediatric cancer
treatment in Lao People’s Democratic Republic at the Lao-Korea National
Children’s Hospital. Pediatr Hematol Oncol . Published online
2018.
11. Mostert S, Sitaresmi MN, Gundy CM, Sutaryo, Veerman AJP. Influence
of socioeconomic status on childhood acute lymphoblastic leukemia
treatment in Indonesia. Pediatrics . Published online 2006.
12. Sitaresmi MN, Mostert S, Schook RM, Sutaryo, Veerman AJP. Treatment
refusal and abandonment in childhood acute lymphoblastic leukemia in
Indonesia: An analysis of causes and consequences.Psychooncology . Published online 2010.
13. Navarrete M, Rossi E, Brivio E, et al. Treatment of childhood acute
lymphoblastic leukemia in central America: A lower-middle income
countries experience. Pediatr Blood Cancer . Published online
2014.
14. Advani S, Pai S, Venzon D, et al. Acute lymphoblastic leukemia in
India: An analysis of prognostic factors using a single treatment
regimen. Ann Oncol . Published online 1999.
15. Pedrosa F, Coustan-Smith E, Zhou Y, et al. Reduced-dose intensity
therapy for pediatric lymphoblastic leukemia: Long-term results of the
Recife RELLA05 pilot study. Blood . Published online 2020.
16. Sidhom I, Shaaban K, Youssef SH, et al. Reduced-intensity therapy
for pediatric lymphoblastic leukemia: Impact of residual disease early
in remission induction. Blood . Published online 2021.
17. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of
childhood acute lymphoblastic leukemia is predicted by flow cytometric
measurement of residual disease on day 15 bone marrow. J Clin
Oncol . Published online 2009.
18. Hamadeh L, Enshaei A, Schwab C, et al. Validation of the United
Kingdom copy-number alteration classifier in 3239 children with B-cell
precursor ALL. Blood Adv . Published online 2019.
19. Logan C, Koura D TR. Updates in infection risk and management in
acute leukemia. Hematol Am Soc Hematol Educ Progr .
2020;2020(1):135-139.
20. Brown PA, Ji L, Xu X, et al. A Randomized Phase 3 Trial of
Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and
Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic
Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs)
Demonstrates Superior Eff. Blood .
2019;134(Supplement_2):LBA-1-LBA-1.